- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04966221
Functional and Structural Lung Imaging in Chronic Obstructive Pulmonary Disease (FASTCOPD)
This study aims to use novel proton-based MRI techniques to assess lung function and structure in healthy volunteers and patients with chronic obstructive pulmonary disease (COPD) and alpha-1-anti-trypsin deficiency (A1ATD). These novel MRI measures will be compared to matched contemporary clinical diagnostic tools, namely pulmonary function tests (PFTs) and computed tomography (CT) scans. MRI has the advantages of avoiding ionising radiation exposure (unlike CT scans) and can also provide regional measures of lung function (unlike PFTs which provide global measures of function). In addition, these MRI techniques do not require the use of any inhaled or injected contrast agents.
Some patients enrolled in this study will be undergoing a lung volume reduction (LVR) procedure as part of their normal clinical care. LVR is an intervention for patients with severe lung disease and hyperinflation. It is a palliative therapy that helps to reduce lung hyperinflation through insertion of small valves in the airway or surgical removal of parts of the lung. This can lead to improvements in symptoms such as breathlessness and improve exercise tolerance due to better functioning of the lung. In this study, we will explore how lung MRI measures can be used to assess patients before and after an LVR intervention.
This study will take place at the University of Nottingham in collaboration with Nottingham University Hospitals NHS Trust. The study will last for 3 years and participants will be asked to attend a screening visit (lasting up to 1 hour) and either one or two study visits (each lasting up to 3 hours).
Study Overview
Status
Intervention / Treatment
Detailed Description
This is a single centre pilot study. The research team aims to recruit adult healthy volunteers and adult patient volunteers with COPD and A1ATD. We have used similar proton-based MRI techniques in healthy volunteers and people with other lung diseases and the MRI scans have been well tolerated.
All participants will be adults (both male and female) who can give informed consent and are able to undertake the study procedures. Potential participants who cannot have an MRI scan for safety reasons (e.g. have a pacemaker) will not be recruited. During study visits, all research activities will be observed by a member of the research team.
During the screening visit (following consent), the following information and measures will be taken:
Relevant past medical history, COPD assessment tool (questionnaire), height, weight, blood pressure and pulse oximetry.
During study visits, a combination of structural and functional lung MRI scans will be performed with the participant lying in the scanner. Participants will be asked to breathe normally during scans and may also be asked to perform breathing manoeuvres such as holding their breath temporarily.
The participants will be assigned unique codes, and their data will be anonymised. Participants' medical reports will only be accessed for study purposes and will be treated as confidential.
The investigators will aim to use the data to plan future studies, and the data from this study may contribute to publications and presentations. Participants will not be identified in any publications arising from the research. The data obtained will be published without any identifying information.
Study Type
Enrollment (Anticipated)
Contacts and Locations
Study Contact
- Name: Jonathan Philip Brooke
- Phone Number: 01158231154
- Email: jonathan.brooke@nottingham.ac.uk
Study Contact Backup
- Name: Zachary Peggs
- Phone Number: 01158231154
- Email: pmyzp@exmail.nottingham.ac.uk
Study Locations
-
-
Nottinghamshire
-
Nottingham, Nottinghamshire, United Kingdom, NG7 2QX
- Recruiting
- Sir Peter Mansfield Imaging Centre, University of Nottingham
-
Contact:
- Richard Bowtell, PhD
- Email: richard.bowtell@nottingham.ac.uk
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
The study population will include up to 25 participants in each of the three workstreams:
Workstream 1 - Adult healthy volunteers Workstream 2 - Adults with chronic obstructive pulmonary disease Workstream 3 - Adults with COPD due to alpha-1-antitrypsin deficiency - A1ATD
Description
Workstream 1 Inclusion criteria (Adult Healthy Volunteers)
- Male or female aged 18 years and over
- Capacity to give informed consent
- Normal blood pressure (systolic BP > 90 mmHg and diastolic BP >50 mmHg)
- Resting heart rate > 50bpm
- For women, negative urinary β-hCG at the screening and subsequent visits (where clinical uncertainty of pregnancy)
- Subject able to hold breath for 10 seconds
- Subject able to understand the requirements of the study and to cooperate with the study procedures
- Subject has normal lung function by spirometry criteria
- Smoking history of > 10 pack years of tobacco smoking
Workstream 1 Exclusion criteria (Adult Healthy Volunteers)
- Unsuitable for MRI scanning (e.g. have metal implants or pacemaker or contraindicated following questionnaire)
- Subject deemed unlikely to comply with instructions during imaging
- Subject not deemed fit enough to tolerate procedure
- Subject deemed unsuitable by clinical investigator for other reasons
- Abnormal spirometry
Workstream 2 Inclusion criteria (Adults with chronic obstructive pulmonary disease)
- Male or female aged 18 years and over
- Capacity to give informed consent
- Normal blood pressure (systolic BP > 90 mmHg and diastolic BP >50 mmHg)
- Resting heart rate > 50bpm
- For women, negative urinary β-hCG at the screening and subsequent visits (where clinical uncertainty of pregnancy)
- Subject able to hold breath for 10 seconds
- Subject able to understand the requirements of the study and to cooperate with the study procedures
- Diagnosis of COPD made by respiratory physician and confirmed by spirometry criteria (FEV1/FVC ratio < 0.7) and > 10 pack years of tobacco smoking.
Workstream 2 Exclusion criteria (Adults with chronic obstructive pulmonary disease)
- Unsuitable for MRI scanning (e.g. have metal implants or pacemaker or contraindicated following questionnaire)
- Acute illness considered to be of sufficient severity to prevent safe MRI scanning. In this instance, the subject will be invited to be rescreened > 4 weeks later.
- Subject deemed unlikely to comply with instructions during imaging
- Subject not deemed fit enough to tolerate procedure
- Subject deemed unsuitable by clinical investigator for other reasons
Workstream 3 Inclusion criteria (Adults with COPD due to alpha-1-antitrypsin deficiency - A1ATD)
- Male or female aged 18 years and over
- Capacity to give informed consent
- Normal blood pressure (systolic BP > 90 mmHg and diastolic BP >50 mmHg)
- Resting heart rate > 50bpm
- For women, negative urinary β-hCG at the screening and subsequent visits (where clinical uncertainty of pregnancy)
- Subject able to hold breath for 10 seconds
- Subject able to understand the requirements of the study and to cooperate with the study procedures
- Diagnosis of A1ATD (PiZZ or PiZ-) and either evidence of emphysema on a previous clinical CT scan or evidence of airways obstruction
Workstream 3 Exclusion criteria (Adults with COPD due to alpha-1-antitrypsin deficiency - A1ATD)
- Unsuitable for MRI scanning (e.g. have metal implants or pacemaker or contraindicated following questionnaire)
- Acute illness considered to be of sufficient severity to prevent safe MRI scanning. In this case, the subject will be rescreened >4 weeks later
- Subject deemed unlikely to comply with instructions during imaging
- Subject not deemed fit enough to tolerate procedure
- Subject deemed unsuitable by clinical investigator for other reasons
Study Plan
How is the study designed?
Design Details
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
---|---|
Adult healthy volunteers
Adult healthy volunteers, age matched to patient volunteers.
Will undergo a combination of functional and structural lung MRI scans.
|
Participants will have a combination of structural and functional lung MRI scans.
These scans will involve lying in a conventional MRI scanner while free breathing and may include additional breathing manoeuvres such as temporarily holding breath.
|
Adults with Chronic Obstructive Pulmonary Disease
Will undergo a combination of functional and structural lung MRI scans.
Some participants in this cohort will have lung volume reduction (LVR) as part of their normal clinical care.
These participants will be given the option to attend two study visits - one before and one after LVR.
|
Participants will have a combination of structural and functional lung MRI scans.
These scans will involve lying in a conventional MRI scanner while free breathing and may include additional breathing manoeuvres such as temporarily holding breath.
|
Adults with alpha-1-antitrypsin deficiency
Will undergo a combination of functional and structural lung MRI scans.
|
Participants will have a combination of structural and functional lung MRI scans.
These scans will involve lying in a conventional MRI scanner while free breathing and may include additional breathing manoeuvres such as temporarily holding breath.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
To acquire structural and functional proton-based lung MRI scans from patients with COPD and COPD due to A1ATD and produce baseline data for these groups to inform future clinical studies
Time Frame: 3 years
|
To compare functional MRI outcomes with matched clinical physiological data (e.g.
pulmonary function tests) To compare structural lung images with matched conventional imaging techniques done for clinical reasons (e.g.
computed tomography) of the diaphragm and lungs
|
3 years
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
To assess the ability of participants of each group to adhere to the protocols, thus informing the study design of future trials
Time Frame: 3 years
|
3 years
|
To assess any change of MR outcomes across study visits for those participants undertaking more than one MR scanning visit.
Time Frame: 3 years
|
3 years
|
To assess any change of MR outcomes across study visits for participants who undergo LVR
Time Frame: 3 years
|
3 years
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: Jonathan Philip Brooke, The University of Nottingham
- Principal Investigator: Zachary Peggs, The University of Nottingham
Study record dates
Study Major Dates
Study Start (ACTUAL)
Primary Completion (ANTICIPATED)
Study Completion (ANTICIPATED)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ACTUAL)
Study Record Updates
Last Update Posted (ACTUAL)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 21048
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Chronic Obstructive Pulmonary Disease
-
Spire, Inc.ResMedCompletedSevere Chronic Obstructive Pulmonary Disease | Moderate Chronic Obstructive Pulmonary DiseaseUnited States
-
Karaganda Medical UniversityCompletedChronic Obstructive Pulmonary Disease | Chronic Obstructive Pulmonary Disease Moderate | Chronic Obstructive Pulmonary Disease SevereKazakhstan
-
Randall DebattistaUniversity of Malta, Faculty of Health SciencesNot yet recruitingChronic Obstructive Pulmonary Disease Moderate | Acute Exacerbation of COPD | Chronic Obstructive Pulmonary Disease Severe
-
Cukurova UniversityCompletedAnesthesia | Chronic Obstructive Pulmonary Disease Moderate | Lungcancer | Chronic Obstructive Pulmonary Disease Severe | Chronic Obstructive Pulmonary Disease MildTurkey
-
National Taipei University of Nursing and Health...TerminatedChronic Pulmonary Disease | Chronic Obstructive Pulmonary Disease Exacerbation | Chronic Obstructive Pulmonary Disease With ExacerbationTaiwan
-
Taipei Medical UniversityUnknownChronic Obstructive Pulmonary Disease Severe | Chronic Obstructive Pulmonary Disease End StageTaiwan
-
Kırıkkale UniversityRecruitingCOPD (Chronic Obstructive Pulmonary Disease)Turkey
-
Hopital FochAir Liquide SARecruitingChronic Obstructive Pulmonary Disease SevereFrance
-
Fundación para la Investigación del Hospital Clínico...Not yet recruitingCOPD, Chronic Obstructive Pulmonary DiseaseSpain
-
Canandaigua VA Medical CenterRecruitingChronic Obstructive Pulmonary Disease ModerateUnited States
Clinical Trials on Lung MRI scan
-
University of Michigan Rogel Cancer CenterDepartment of Health and Human ServicesCompleted
-
Fayoum University HospitalCompletedCoronary Artery Disease | Valvular Heart DiseaseEgypt
-
University of ChicagoRecruitingBreast CancerUnited States
-
Assistance Publique - Hôpitaux de ParisVaincre la Mucoviscidose; French society of cystic fibrosis; AFDPHE : newborn...Completed
-
Philips Clinical & Medical Affairs GlobalCompletedPleural Effusion | Lung ConsolidationUnited States
-
University Hospital, BordeauxMinistry of Health, FranceActive, not recruitingCystic FibrosisFrance
-
University Hospital, BordeauxSFGM-TCRecruitingBronchiolitis ObliteransFrance
-
University of VirginiaNational Institutes of Health (NIH)RecruitingChronic Rejection of Lung TransplantUnited States
-
Jeffrey A. Lieberman, MDTerminated